Skip to main content

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Dose Escalation/ Expansion Trial of CA-4948 as Monotherapy and in Combination With Azacitidine or Venetoclax in Patients With AML or MDS

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Dose Escalation/ Expansion Trial of CA-4948 as Monotherapy and in Combination With Azacitidine or Venetoclax in Patients With AML or MDS

A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients

A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Virtual Reality Goggle Utilization for Venipuncture Distraction

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about Virtual Reality Goggle Utilization for Venipuncture Distraction

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

CARE Mentalizing-Focused Parenting Group Outcomes Study

Submitted by Anonymous (not verified) on Mon, 05/23/2022 - 14:03
  • Read more about CARE Mentalizing-Focused Parenting Group Outcomes Study

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 208
  • Page 209
  • Page 210
  • Page 211
  • Page 212
  • Page 213
  • Page 214
  • Page 215
  • Page 216
  • …
  • Next page Next
  • Last page Last
Subscribe to